Indications and uses
This Homeopathic product of natural source provides symptomatic relief from ringing and buzzing in the ears.
This Homeopathic product of natural source provides symptomatic relief from ringing and buzzing in the ears.
Adults: Allow 3 pellets to dissolve under the tongue 3 times a day or as directed by a health professional. For adult use only. Do not exceed recommended dosage.
Kalium bromatum 3X
Nux vomica 4X
China rubra 4X
Sulphur 4X
Sanguinaria canadensis 4X
Dulcamara 3X
Hydrastis canadensis 3X
Arnica montana 4X
Bryonia alba 4X
Causticum 6X
Manufactured according to the Homeopathic Pharmacopoeia of the United States (HPUS)
Helps relieve ringing and buzzing in the ears
This Homeopathic product of natural source provides symptomatic relief from ringing and buzzing in the ears.
If symptoms persist or worsen, discontinue use and contact a health professional.
As with any drug, if you are pregnant or nursing a baby, seek the advice of a health professional before using this product.
Keep this and all medications out of reach of children.
Adults: Allow 3 pellets to dissolve under the tongue 3 times a day or as directed by a health professional.
For adult use only. Do not exceed recommended dosage.
Do not use if cap seal is broken.
Homeolab USA Inc., 3025 De L'Assomption Blvd., Montreal, QC H1N 2H2 Canada
PRODUCT OF CANADA
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 60512-9054-1 | 2025-12-28 | C162847 | 48780-1 | 9d75b9d1-2b65-f424-e053-dadaa90a57ce | DRUG FACTS |
| 60512-9054-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-2b65-f424-e053-dadaa90a57ce | DRUG FACTS |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 60512-9054 | TINNITUS RELIEF (KALIUM BROMATUM, NUX VOMICA, CHINA RUBRA, SULPHUR, SANGUINARIA CANADENSIS, DULCAMARA, HYDRASTIS CANADENSIS, ARNICA MONTANA, BRYONIA ALBA, CAUSTICUM) PELLET [HOMEOLAB USA INC.] | 2 | Legacy NDC | 20140508_566aca29-8da3-4c21-9667-4e5eef860b6d.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ARNICA MONTANA | ACTIVE INGREDIENT | O80TY208ZW | 2 | |
| BRYONIA ALBA ROOT | ACTIVE INGREDIENT | T7J046YI2B | 2 | |
| CAUSTICUM | ACTIVE INGREDIENT | DD5FO1WKFU | 2 | |
| CINCHONA OFFICINALIS BARK | ACTIVE INGREDIENT | S003A158SB | 2 | |
| GOLDENSEAL | ACTIVE INGREDIENT | ZW3Z11D0JV | 2 | |
| POTASSIUM BROMIDE | ACTIVE INGREDIENT | OSD78555ZM | 2 | |
| SANGUINARIA CANADENSIS ROOT | ACTIVE INGREDIENT | N9288CD508 | 2 | |
| SOLANUM DULCAMARA STEM | ACTIVE INGREDIENT | IR986LE7DF | 2 | |
| STRYCHNOS NUX-VOMICA SEED | ACTIVE INGREDIENT | 269XH13919 | 2 | |
| SULFUR | ACTIVE INGREDIENT | 70FD1KFU70 | 2 | |
| ARNICA MONTANA | ACTIVE MOIETY | O80TY208ZW | 2 | |
| BROMIDE ION | ACTIVE MOIETY | 952902IX06 | 2 | |
| BRYONIA ALBA ROOT | ACTIVE MOIETY | T7J046YI2B | 2 | |
| CAUSTICUM | ACTIVE MOIETY | DD5FO1WKFU | 2 | |
| CINCHONA OFFICINALIS BARK | ACTIVE MOIETY | S003A158SB | 2 | |
| GOLDENSEAL | ACTIVE MOIETY | ZW3Z11D0JV | 2 | |
| SANGUINARIA CANADENSIS ROOT | ACTIVE MOIETY | N9288CD508 | 2 | |
| SOLANUM DULCAMARA STEM | ACTIVE MOIETY | IR986LE7DF | 2 | |
| STRYCHNOS NUX-VOMICA SEED | ACTIVE MOIETY | 269XH13919 | 2 | |
| SULFUR | ACTIVE MOIETY | 70FD1KFU70 | 2 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | 2 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 60512-9054 | 60512-9054-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| POTASSIUM BROMIDE | OSD78555ZM | ACTIB |
| STRYCHNOS NUX-VOMICA SEED | 269XH13919 | ACTIB |
| CINCHONA OFFICINALIS BARK | S003A158SB | ACTIB |
| SULFUR | 70FD1KFU70 | ACTIB |
| SANGUINARIA CANADENSIS ROOT | N9288CD508 | ACTIB |
| SOLANUM DULCAMARA STEM | IR986LE7DF | ACTIB |
| GOLDENSEAL | ZW3Z11D0JV | ACTIB |
| ARNICA MONTANA | O80TY208ZW | ACTIB |
| BRYONIA ALBA ROOT | T7J046YI2B | ACTIB |
| CAUSTICUM | DD5FO1WKFU | ACTIB |
| SUCROSE | C151H8M554 | IACT |
| LACTOSE | J2B2A4N98G | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, EMULSION / INTRAVENOUS | 970 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | 1 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / SUBLINGUAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 2000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 900 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUPPOSITORY / RECTAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAVENOUS | 203.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / BUCCAL | 296.7 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / BUCCAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / RESPIRATORY (INHALATION) | 90 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 7560 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / RECTAL | 20 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / BUCCAL | NA |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 470d3afd-c433-4a7f-e063-6394a90a75c9 | 566aca29-8da3-4c21-9667-4e5eef860b6d | 2025-12-28 | Warnings | 566aca29-8da3-4c21-9667-4e5eef860b6d |
Adverse event summaries are temporarily unavailable. Other product information remains available.